Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 3Nausea 2Multiple Myeloma 2Cachexia 2Anorexia 2Weight Loss 1Vomiting 1Squamous Cell Carcinoma of Head and Neck 1Prosthesis Failure 1Opioid-Related Disorders 1Nutrition Disorders 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancer 1

Interventions

pembrolizumab 61Cisplatin 37Carboplatin 23Radiotherapy 21Cetuximab 19Magnetic Resonance Spectroscopy 18Paclitaxel 17Specimen Handling 13Docetaxel 12Fluorouracil 11Nivolumab 10tislelizumab 9Surgical Procedures, Operative 8Radiotherapy, Intensity-Modulated 7Radiation 7cemiplimab 6Standard of Care 6Platinum 6Chemoradiotherapy 6Biopsy 61,2-diaminocyclohexaneplatinum II citrate 6toripalimab 5Drug Therapy 5130-nm albumin-bound paclitaxel 5atezolizumab 4Taxes 4Ipilimumab 4Immunotherapy 4Fluorodeoxyglucose F18 4Cyclophosphamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Squamous Cell Carcinoma of Head and Neck × Olanzapine × Clear all
NCT06995508 2026-02-17

Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

Roswell Park Cancer Institute

Phase 2 Recruiting
66 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡